Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric eltrombopag pharmacokinetics in severe aplastic anemia
NL-OMON50357Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in aplastic anemia, sponsored by Novartis. Primary endpoints: Eltrombopag pharmacokinetic parameters at week 2 and Eltrombopag pharmacokinetic parameters at week 12. Planned start Aug 2017; status: withdrawn.
02
Drugs
eltrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NL-OMON50357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50357.